Better Care for PFAS Patients Act of 2026 mandates periodic clinical guidance on PFAS health effects.
The Better Care for PFAS Patients Act of 2026 requires the Director of the Agency for Toxic Substances and Disease Registry to collaborate with the National Academies of Sciences, Engineering, and Medicine or another appropriate entity. This collaboration involves assessing the health effects of per- and polyfluoroalkyl substances (PFAS) and formulating clinical recommendations. The entity must issue up-to-date clinical guidance, post it on the Agency's public website, and disseminate it to state and local public health authorities and health care professionals.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.